Rocket Lab 16 January 2026 - 13 February 2026

Rocket Lab shares fell 5.35% to $75.79 by Monday afternoon, extending losses to 24% below their January high. The drop follows reports that Congress pulled funding for NASA’s Mars Sample Return mission, for which Rocket Lab had proposed a $4 billion role. Investors remain focused on the company’s dependence on government contracts and delays in its Neutron rocket program. Rocket Lab will report Q4 and full-year results on Feb. 26.

Rocket Lab shares rose 1.8% to $88.57 Wednesday after two volatile sessions. The company confirmed its Neutron rocket’s Stage 1 tank ruptured during a qualification test and is still assessing the impact on the launch schedule. Fourth-quarter and full-year results are due Feb. 26.

Rocket Lab shares rose 8% Tuesday before slipping after hours, following a recent Neutron Stage 1 tank rupture that cast uncertainty on the rocket’s launch timeline. The stock traded near $87, up from $80.48, after rebounding from a 9.5% drop Monday. Investors await the late-February earnings call for updates on the Neutron program. The company also secured an $816 million U.S. defense contract.

Rocket Lab shares closed up 1.1% at $88.90 Friday, then slipped 0.4% after hours following news of a Stage 1 tank rupture during Neutron rocket testing. The company is assessing possible schedule impacts. Earlier, Rocket Lab completed its first Electron launch of 2026 and plans another mission next week. Director Jon Olson sold 15,205 shares on Jan. 20 under a pre-arranged plan.

Rocket Lab shares rose 1.7% to $89.28 in after-hours trading Wednesday after dropping 1.5% during the session and nearly 9% over the last two days. Traders are focused on an Electron rocket launch attempt scheduled for Jan. 22 and quarterly results expected around Feb. 26.